Item 7.01 Regulation FD Disclosure.

On July 1, 2020, Krystal Biotech, Inc. (the "Company") issued a press release announcing updated positive results from its Phase 1/2 clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis (ARCI) associated with mutations in the TGM1 gene. A copy of the press release and a copy of the Company's corporate presentation reflecting such updates regarding KB105 are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K.

This information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing.

Item 9.01. Financial Statements and Exhibits.




(d)  Exhibits



Exhibit
Number                                 Description of Document

99.1           Press Release dated July 1, 2021.

99.2           Corporate Presentation dated July 2021

104          Cover Page Interactive Data file (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses